In his weekly clinical update, Dr. Griffin discusses the new risk assessment for the H5N1 avian flu viruses, the development of monoclonal antibody – based blocking ELISA for detecting SARS – CoV – 2 exposure in animals, repeated antibiotic exposure and risk of hospitalization and death following COVID – 19 infection, COVID – 19 rebound study: a prospective cohort study to evaluate viral and symptom rebound differences in participants treated with Nirmatrelvir plus Ritonavir versus untreated controls, exaggerated blood pressure elevation in response to orthostatic challenge a post – acute sequelae of SARS – CoV – 2 infection( PASC ) after hospitalization, long term follow – up of a multicenter cohort of COVID – 19 patients with pulmonary embolism, and risk of cardiovascular disease after COVID‐19 diagnosis among adults with and without diabetes.
Click arrow to play
Download TWiV 1025( 21 MB.mp3, 35 min )
Subscribe( free ): & nbsp, Apple Podcasts, & nbsp, Google Podcasts, & nbsp, RSS, & nbsp, email
Become a & nbsp, patron & nbsp, of & nbsp, TWiV!
Links for this episode
- New risk assessment & nbsp, for H5N1 avian flu viruses ( CDC )
- Development of monoclonal antibody – based blocking ELISA for detecting SARS – CoV – 2 exposure ( Virology )
- Repeated antibiotic exposure and risk of hospitalization and death following COVID – 19 infection( eClinicalMedicine )
- COVID – 19 Rebound Study( CID )
- Exaggerated blood pressure elevation in response to orthostatic challenge ( AN)
- Long term follow – up of a multicenter cohort of COVID – 19 patients with pulmonary embolism ( TR )
- Risk of Cardiovascular disease after COVID‐19 diagnosis among adults with and without Diabetes ( JAHA )
- Contribute to our FIMRC fundraiser at PWB
- Letters read on TWiV 1025
- Dr. Griffin &# 8217, s COVID treatment summary( pdf )
- Timestamps by & nbsp, Jolene. Thanks!
Intro music is by & nbsp, Ronald Jenkees
Send your questions for Dr. Griffin to daniel @ microbe.tv
This Week in Virology published the post-TWiV 1025: Clinical update with Dr. Daniel Griffin.